CagriSema is an investigational medicine and is not currently authorised for prescribing in the United Kingdom. Clinical decisions must always be made by a qualified healthcare professional following MHRA and NICE guidance.

Table of Contents

1. Introduction

CagriSema is a next-generation investigational injectable medication developed by Novo Nordisk for the treatment of obesity, overweight, and metabolic disease. It represents a major innovation in obesity pharmacotherapy by combining two hormonal pathways into a single, once-weekly injection: cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist).

Obesity is a chronic, relapsing disease associated with type 2 diabetes, cardiovascular disease, fatty liver disease, PCOS, sleep apnoea, and reduced life expectancy. In the UK, demand for effective, medically supervised weight loss treatments has increased significantly, particularly within private weight loss clinics and community pharmacies. CagriSema has generated global attention due to its Phase 3 trial results showing unprecedented levels of weight reduction for a pharmacological therapy [1].

2. What Is CagriSema?

CagriSema is a fixed-dose combination injection consisting of:

• Semaglutide – a GLP-1 receptor agonist already approved in the UK as Wegovy (for obesity) and Ozempic (for type 2 diabetes).
• Cagrilintide – a long-acting synthetic analogue of the hormone amylin, currently investigational.

The medication is administered once weekly via subcutaneous injection and is designed for long-term use alongside lifestyle intervention.

3. Mechanism of Action (How CagriSema Works)

CagriSema combines two hormones (or hormone-like analogues) that influence appetite and metabolism.

1) Semaglutide (GLP-1 receptor agonist)

GLP-1 receptor agonists can:

• Increase satiety and reduce appetite
• Slow gastric emptying (which can help people feel fuller sooner)
• Improve glucose regulation (especially relevant for type 2 diabetes)

2) Cagrilintide (amylin analogue)

Amylin is a satiety hormone co-secreted with insulin. Cagrilintide is designed to mimic amylin’s effects—supporting fullness and reduced food intake—via central appetite pathways.

Why combine them?

The Phase 3 programme was built around the rationale that two complementary mechanisms may produce greater weight loss than either alone.

3.1 Semaglutide (GLP-1 Receptor Agonist)

Semaglutide:

• Acts on GLP-1 receptors in the brain to increase satiety
• Slows gastric emptying, reducing hunger
• Enhances glucose-dependent insulin secretion
• Lowers glucagon secretion
• Improves HbA1c and insulin sensitivity

3.2 Cagrilintide (Amylin Analogue)

Amylin is co-secreted with insulin after meals and contributes to:

• Appetite suppression
• Delayed gastric emptying
• Reduced post-prandial glucose excursions

Cagrilintide is engineered for prolonged action, enhancing fullness signals and reducing caloric intake.

3.3 Why the Combination Matters

By combining GLP-1 and amylin pathways, CagriSema provides complementary and synergistic appetite suppression. Phase 3 data demonstrate superior weight loss compared with either agent alone [1][2].

4. Clinical Trial Evidence (Phase 3 REDEFINE Programme)

4.1 REDEFINE 1 Trial (Without Diabetes)

• Population: Adults with overweight or obesity (BMI ≥27)
• Duration: 68 weeks
• Mean weight loss: 20.4% with CagriSema vs 3.0% with placebo
• Results exceeded those seen with semaglutide monotherapy
• Significant improvements in waist circumference, lipids, and blood pressure [1]

4.2 REDEFINE 2 Trial (With Type 2 Diabetes)

• Population: Adults with type 2 diabetes and overweight/obesity
• Duration: 68 weeks
• Mean weight loss: 13.7% with CagriSema vs 3.4% placebo
• HbA1c ≤6.5% achieved in a significantly higher proportion of patients
• Improved glycaemic control without excess hypoglycaemia [2]

4.3 Interpretation of Results

Patients with diabetes typically lose less weight than non-diabetic patients. Despite this, CagriSema delivered clinically meaningful weight loss and metabolic improvement, positioning it as a strong future option for diabesity management.

5. Safety Profile and Side Effects

5.1 Common Side Effects

The most frequently reported adverse events were gastrointestinal:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal discomfort

In REDEFINE 2, GI events occurred in 72.5% of treated patients vs 34.4% placebo, mostly mild-to-moderate and transient [2].

5.2 Discontinuation Rates

Treatment discontinuation due to side effects was comparable to existing GLP-1 receptor agonists, suggesting acceptable tolerability under medical supervision.

5.3 Safety Considerations

Caution would be required in:

• Patients with severe gastrointestinal disease
• History of pancreatitis
• Patients on insulin or sulfonylureas
• Pregnancy and breastfeeding
• Eating disorders

The MHRA has warned against misuse of GLP-1 medicines purchased online without supervision [5].

6. Regulatory Status (UK & Global)

6.1 United States

Novo Nordisk submitted CagriSema for FDA approval in 2024. A regulatory decision is expected in 2026 [3].

6.2 CagriSema UK

CagriSema is not currently authorised by the MHRA. The UK regulatory database lists the product as “not available at present” [4]. It is not available via NHS or private prescription.

7. Comparison With Existing Weight Loss Injections

7.1 Wegovy (Semaglutide 2.4 mg)

• NICE-recommended for obesity in specialist settings
• Average weight loss ~15%
• Single-hormone mechanism

7.2 Tirzepatide

• Dual GLP-1/GIP agonist
• Strong weight loss results
• Different mechanism to amylin-based therapy

7.3 CagriSema

• Dual GLP-1 + amylin
• Highest mean weight loss in trials to date
• Investigational but highly promising

8. Who May Be Eligible (If Approved)

Likely criteria include:

• BMI ≥30
• BMI ≥27 with comorbidities
• Type 2 diabetes with excess weight
• Failure of lifestyle intervention alone

Final eligibility will depend on NICE and MHRA guidance.

9. Medcare Health Clinic & Pharmacy Approach

Medcare Health Clinic & Pharmacy provides safe, regulated and ethical weight management services across the UK and Preston, including:

• Private weight loss consultations
• Medication reviews
• Semaglutide prescribing where appropriate
• Ongoing monitoring and support
• Protection against counterfeit injections

Patients searching for “weight loss injections near me”, “private obesity clinic London”, or “semaglutide clinic UK” can access trusted care through Medcare.

10. FAQ Section

Is CagriSema available in the UK?

No. CagriSema is not yet approved in the UK.

Is CagriSema better than Wegovy?

Clinical trials show greater average weight loss, but it is not yet available.

Can I buy CagriSema online?

No legitimate supply exists. Online products are unsafe.

How much weight can I lose?

Trials show average losses of 13–20%, individual results vary.

Is CagriSema safe?

Trials indicate an acceptable safety profile under medical supervision.

11. Conclusion

CagriSema represents one of the most significant advances in obesity and metabolic medicine to date. While it is not yet available in the UK, Phase 3 evidence suggests it may redefine medical weight loss standards. Medcare Health Clinic & Pharmacy remains committed to evidence-based, patient-centred care and will support patients as new treatments emerge.

12. References

Rubino D et al. Cagrilintide–Semaglutide Combination Therapy for Weight Loss. New England Journal of Medicine, 2024.
Davies M et al. Cagrilintide–Semaglutide in Adults with Type 2 Diabetes. New England Journal of Medicine, 2024.
Novo Nordisk Investor Reports and Regulatory Filings.
Medicines and Healthcare products Regulatory Agency (MHRA) Product Database.
MHRA Drug Safety Update: GLP-1 Receptor Agonists and Weight Loss.